A platform-structured medical technology company focused on recurring revenue, operating leverage, and disciplined long-term development.
Medfiniti is a platform-structured medical technology company designed to align intellectual property, commercialization infrastructure, and recurring physician-driven revenue within a single operating architecture.
Procedure-based and consumable revenue creates recurring economics tied directly to physician utilization.
Core technology is protected by 1 issued patent and 2 patents pending, held within a dedicated intellectual property structure that supports long-term defensibility.
Shared infrastructure supports commercialization, operating leverage, and disciplined expansion over time.
The platform structure supports selective future regional growth across targeted international markets.
The corporate architecture separates ownership, management, and operating activity in a form suited to institutional capital.
Gen 1 (launched 2023) performed 15,000+ procedures. Gen 2 (launched February 2026) expands platform foundation with enhanced architecture. Future generations planned to extend capability.
Platform gross margins exceed 90%, driven primarily by low device manufacturing costs.
"HemWell MD has 51 active centers generating live revenue across all four major ASC networks — USPI, SCA, GI Alliance, and HCA — driven mostly by organic inbound demand before a single structured enterprise push. Growth to date has been self-constrained by device inventory and support bandwidth, not demand."
Enterprise rollout planning is underway with four of the largest GI and ASC networks. Formal agreements are in negotiation, with regulatory pathway clearance and CPT coding already established across major reimbursement environments. The operating challenge is scaling infrastructure to meet partner demand.
Most medical devices require 12–24 months of physician utilization before the manufacturer recovers placement costs. Medfiniti's model developed for HemWell MD recovers in approximately one active month — fundamentally changing the risk profile of scaling.
The HemWell MD Platform's expansion is sequenced across near-term network growth, selective regional markets, and longer-term regulatory advancement.
Growth in physician adoption remains the primary near-term driver of recurring operating revenue through HemWell MD.
The platform structure supports selective future international growth through disciplined regional commercialization efforts.
Additional indications and regulatory progress may expand the addressable market while leveraging existing infrastructure.
This website contains forward-looking statements and does not constitute an offer or solicitation to purchase securities. See our Legal Notices page for important disclosures and risk information.